Study: NCT05214872

Intervention type: DIAGNOSTIC_TEST
Intervention: klotho
Description: klotho \[ng/ml\] - was analyzed in the serum by Human KL(Klotho) \[ng/ml\] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroblast growth factor 23 (FGF-23)
Description: FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroblast growth factor 23 (FGF-23)
Description: FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroblast growth factor 23 (FGF-23)
Description: FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroblast growth factor 23 (FGF-23)
Description: FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroblast growth factor 23 (FGF-23)
Description: FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of calcium and phosphate metabolism
Description: * total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of calcium and phosphate metabolism
Description: * total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of calcium and phosphate metabolism
Description: * total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of calcium and phosphate metabolism
Description: * total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of calcium and phosphate metabolism
Description: * total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: liver enzymes activity assessment
Description: activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: liver enzymes activity assessment
Description: activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: liver enzymes activity assessment
Description: activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: liver enzymes activity assessment
Description: activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: liver enzymes activity assessment
Description: activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: total protein and albumin
Description: * total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: total protein and albumin
Description: * total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: total protein and albumin
Description: * total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: total protein and albumin
Description: * total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: total protein and albumin
Description: * total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: creatinine and urea
Description: * creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: creatinine and urea
Description: * creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: creatinine and urea
Description: * creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: creatinine and urea
Description: * creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: creatinine and urea
Description: * creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (2)
Description: myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (2)
Description: myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (2)
Description: myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (2)
Description: myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (2)
Description: myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (3) sRAGE
Description: soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (3) sRAGE
Description: soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (3) sRAGE
Description: soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (3) sRAGE
Description: soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (3) sRAGE
Description: soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups
Description: * methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups
Description: * methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups
Description: * methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups
Description: * methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups
Description: * methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected electrolytes assessment
Description: * potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected electrolytes assessment
Description: * potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected electrolytes assessment
Description: * potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected electrolytes assessment
Description: * potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: selected electrolytes assessment
Description: * potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-brain natriuretic peptide (NT-proBNP)
Description: NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-brain natriuretic peptide (NT-proBNP)
Description: NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-brain natriuretic peptide (NT-proBNP)
Description: NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-brain natriuretic peptide (NT-proBNP)
Description: NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-brain natriuretic peptide (NT-proBNP)
Description: NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.

Intervention type: OTHER
Intervention: estimated glomerular filtration rate (eGFR) calculation
Description: eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.

Intervention type: OTHER
Intervention: estimated glomerular filtration rate (eGFR) calculation
Description: eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.

Intervention type: OTHER
Intervention: estimated glomerular filtration rate (eGFR) calculation
Description: eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.

Intervention type: OTHER
Intervention: estimated glomerular filtration rate (eGFR) calculation
Description: eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.

Intervention type: OTHER
Intervention: estimated glomerular filtration rate (eGFR) calculation
Description: eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.